J Peter Van Tintelen

List of Publications by Year
in descending order

106	7,179	66343	60623
papers	citations	42 h-index	81 g-index

111	111	111	6523
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.7	494
2	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation: Cardiovascular Genetics, 2015, 8, 437-446.	5.1	370
3	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	7.1	369
4	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	2.2	338
5	Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2006, 113, 1650-1658.	1.6	326
6	Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGenâ€™s Inherited Cardiomyopathy Expert Panel. Genetics in Medicine, 2018, 20, 351-359.	2.4	283
7	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002460.	3.6	267
8	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213
9	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2011, 123, 2690-2700.	1.6	194
10	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	2.2	159
11	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	21.4	155
12	High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. American Heart Journal, 2007, 154, 1130-1139.	2.7	150
13	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	3.8	148
14	Outcome in Phospholamban R14del Carriers. Circulation: Cardiovascular Genetics, 2014, 7, 455-465.	5.1	146
15	Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm, 2009, 6, 1574-1583.	0.7	143
16	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.7	135
17	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 512-521.	7.1	127
18	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circulation Genomic and Precision Medicine, 2021, 14, e003273.	3.6	112

#	Article	IF	Citations
19	Activation Delay and VT Parameters in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Toward Improvement of Diagnostic ECG Criteria. Journal of Cardiovascular Electrophysiology, 2008, 19, 775-781.	1.7	102
20	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovascular Research, 2017, 113, 1521-1531.	3.8	98
21	Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm, 2010, 7, 1058-1064.	0.7	97
22	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	7.1	84
23	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
24	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	4.8	82
25	Severe Myocardial Fibrosis Caused by a Deletion of the 5â€™ End of the Lamin A/C Gene. Journal of the American College of Cardiology, 2007, 49, 2430-2439.	2.8	79
26	Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm, 2018, 15, 1097-1107.	0.7	79
27	Family letters are an effective way to inform relatives about inherited cardiac disease. American Journal of Medical Genetics, Part A, 2009, 149A, 357-363.	1.2	77
28	The ARVD/C Genetic Variants Database: 2014 Update. Human Mutation, 2015, 36, 403-410.	2.5	77
29	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	2.2	75
30	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the PediatricÂPopulation. JACC: Clinical Electrophysiology, 2015, 1, 551-560.	3.2	74
31	Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 515-525.	2.8	70
32	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. European Heart Journal, 2016, 37, 755-763.	2.2	68
33	Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon?. Current Opinion in Cardiology, 2007, 22, 185-192.	1.8	67
34	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Diagnostic Task Force Criteria. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 126-133.	4.8	65
35	Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	2.2	63
36	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. European Heart Journal, 2015, 36, 872-881.	2.2	56

#	Article	IF	Citations
37	Isolated Subepicardial Right Ventricular Outflow Tract Scar in Athletes With VentricularÂTachycardia. Journal of the American College of Cardiology, 2017, 69, 497-507.	2.8	56
38	The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. European Heart Journal, 2020, 41, 1393-1400.	2.2	54
39	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriersâ€“reaching the frontiers of individual risk prediction. European Heart Journal, 2021, 42, 2842-2850.	2.2	54
40	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	2.9	50
41	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	1.2	48
42	Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology, 2016, 69, 542-550.	2.9	46
43	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
44	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	8.2	42
45	Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart, 2014, 1, e000116.	2.3	40
46	Pregnancy, cardiomyopathies, and genetics. Cardiovascular Research, 2014, 101, 571-578.	3.8	40
47	Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation. Europace, 2020, 22, 787-796.	1.7	40
48	Mortality of Inherited Arrhythmia Syndromes. Circulation: Cardiovascular Genetics, 2012, 5, 183-189.	5.1	39
49	Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy. Basic Research in Cardiology, 2015, 110, 27.	5.9	38
50	Whole-Exome Sequencing Identifies Pathogenic Variants in TJP1 Gene Associated With Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002123.	3.6	38
51	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circulation Genomic and Precision Medicine, 2019, 12, e002467.	3.6	38
52	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	3.3	38
53	Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genetics in Medicine, 2018, 20, 1374-1386.	2.4	36
54	Large Genomic Rearrangements of Desmosomal Genes in Italian Arrhythmogenic Cardiomyopathy Patients. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	35

#	Article	IF	Citations
55	High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation. PLoS ONE, 2017, 12, e0189489.	2.5	33
56	Fetal methotrexate syndrome: A systematic review of case reports. Reproductive Toxicology, 2019, 87, 125-139.	2.9	33
57	Clinical utility gene card for: Dilated Cardiomyopathy (CMD). European Journal of Human Genetics, 2013, 21, 1185-1185.	2.8	30
58	Relevance of Titin Missense and Non-Frameshifting Insertions/Deletions Variants in Dilated Cardiomyopathy. Scientific Reports, 2019, 9, 4093.	3.3	30
59	Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5. Heart Rhythm, 2020, 17, 945-954.	0.7	28
60	Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). European Journal of Human Genetics, 2014, 22, 293-293.	2.8	27
61	Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome. Circulation Research, 2018, 122, 846-854.	4.5	22
62	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	3.6	21
63	Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. International Journal of Cardiology, 2014, 171, 90-92.	1.7	20
64	Burden of Recurrent and Ancestral Mutations in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
65	Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Failure Reviews, 2017, 22, 263-277.	3.9	18
66	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovascular Pathology, 2017, 30, 23-26.	1.6	17
67	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. European Heart Journal, 2018, 39, 2898-2907.	2.2	17
68	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	2.3	17
69	Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovascular Pathology, 2019, 40, 2-6.	1.6	16
70	Prevalence and Prognostic Impact of Pathogenic Variants in Patients With Dilated Cardiomyopathy Referred for Ventricular Tachycardia Ablation. JACC: Clinical Electrophysiology, 2020, 6, 1103-1114.	3.2	16
71	Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathy. Journal of Medical Genetics, 2020, 57, 23-30.	3.2	16
72	Epicardial differentiation drives fibro-fatty remodeling in arrhythmogenic cardiomyopathy. Science Translational Medicine, 2021, 13, eabf2750.	12.4	16

#	Article	IF	Citations
73	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	1.7	15
74	Phenotypic spectrum of TGFB3 diseaseâ€causing variants in a Dutchâ€French cohort and first report of a homozygous patient. Clinical Genetics, 2020, 97, 723-730.	2.0	15
75	A group approach to genetic counselling of cardiomyopathy patients: satisfaction and psychological outcomes sufficient for further implementation. European Journal of Human Genetics, 2015, 23, 1462-1467.	2.8	14
76	Functional assessment of potential splice site variants in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2014, 11, 2010-2017.	0.7	13
77	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	2.4	13
78	Genetic Evaluation in a Cohort of 126 Dutch Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1191.	2.4	12
79	Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants. Journal of Clinical Medicine, 2020, 9, 545.	2.4	12
80	Desmoplakin Gene Variants and Risk for Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002241.	3.6	11
81	Desmin is essential for the structure and function of the sinoatrial node: implications for increased arrhythmogenesis. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H557-H570.	3.2	11
82	Long-Term Follow-Up Study on the Uptake of Genetic Counseling and Predictive DNA Testing in Inherited Cardiac Conditions. Circulation Genomic and Precision Medicine, 2020, 13, 524-530.	3.6	11
83	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. Circulation Genomic and Precision Medicine, 2018, 11, e001797.	3.6	10
84	Informing relatives at risk of inherited cardiac conditions: experiences and attitudes of healthcare professionals and counselees. European Journal of Human Genetics, 2019, 27, 1341-1350.	2.8	10
85	Echocardiographic Deformation ImagingÂfor Early Detection of GeneticÂCardiomyopathies. Journal of the American College of Cardiology, 2022, 79, 594-608.	2.8	10
86	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 306-318.	3.2	10
87	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace, 2022, 24, 296-305.	1.7	9
88	Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison. European Journal of Human Genetics, 2017, 25, 169-175.	2.8	8
89	Global approaches to cardiogenetic evaluation after sudden cardiac death in the young: A survey among health care professionals. Heart Rhythm, 2021, 18, 1637-1644.	0.7	8
90	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm, 2022, 19, 427-434.	0.7	8

#	Article	IF	Citations
91	QRS prolongation after premature stimulation is associated with polymorphic ventricular tachycardia in nonischemic cardiomyopathy: Results from the Leiden Nonischemic Cardiomyopathy Study. Heart Rhythm, 2016, 13, 860-869.	0.7	7
92	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace, 2022, 24, 285-295.	1.7	7
93	A tailored approach to informing relatives at risk of inherited cardiac conditions: results of a randomised controlled trial. European Journal of Human Genetics, 2022, 30, 203-210.	2.8	7
94	Cardiac Arrest During Spine Surgery in the Prone Position: Case Report and Review of the Literature. World Neurosurgery, 2018, 115, 460-467.e1.	1.3	6
95	Autosomal dominant Marfan syndrome caused by a previously reported recessive FBN1 variant. Molecular Genetics & Genomic Medicine, 2019, 7, e00518.	1.2	6
96	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2022, 19, 1659-1665.	0.7	6
97	Mortality Risk Associated With Truncating Founder Mutations in Titin. Circulation Genomic and Precision Medicine, 2019, 12, e002436.	3.6	5
98	Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010221.	4.8	5
99	Genetic Basis of Dilated Cardiomyopathy in Dogs and Its Potential as a Bidirectional Model. Animals, 2022, 12, 1679.	2.3	5
100	Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circulation Genomic and Precision Medicine, 2020, 13, 548-550.	3.6	4
101	Flotillins in the intercalated disc are potential modulators of cardiac excitability. Journal of Molecular and Cellular Cardiology, 2019, 126, 86-95.	1.9	3
102	Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Research, 2022, 60, 102737.	0.7	3
103	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	2.5	2
104	A tailored approach towards informing relatives at risk of inherited cardiac conditions: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e025660.	1.9	2
105	Terminal osseous dysplasia with pigmentary defects and cardiomyopathy caused by a novel FLNA variant. American Journal of Medical Genetics, Part A, 2021, 185, 3814-3820.	1.2	1
106	Uptake and Patient Perspectives on Additional Testing for Novel Disease-Associated Genes: Lessons from a PAH Cohort. Genes, 2021, 12, 1540.	2.4	1